Narrowband UVB phototherapy for early-stage mycosis fungoides - 01/09/11
Abstract |
Background: Narrowband UVB (NB-UVB) phototherapy has been shown to be effective for the treatment of various dermatoses. Objective: We evaluated the effect of NB-UVB in the treatment of early stage mycosis fungoides (MF). Methods: The response of 24 patients (12 stage IA, 12 stage IB) with patch stage MF to thrice weekly NB-UVB was assessed. Twelve patients had skin phototypes I-III, and 12 had types IV-VI. Seven patients had hypopigmented MF. Mean follow-up period was 29.0 weeks. Results: Thirteen patients (54.2%) had a complete response (CR), 7 (29.2%) had partial response (PR), and 4 (16.7%) had no response. Specimens from a repeat biopsy in 10 patients with CR showed histologic clearing in 9 of them. Upon discontinuation of treatment, 4 patients with CR relapsed, with a mean time to relapse of 12.5 weeks. Conclusion: NB-UVB is a viable, comparably safe, and easily administered alternative in the management of early stage MF. (J Am Acad Dermatol 2002;47:191-7).
Le texte complet de cet article est disponible en PDF.Plan
 | Conflict of interest: None identified. |
| Dr Scherschun was supported by the Clarence S. Livingood Lectureship and Education Fund as the Clarence S. Livingood Clinical Research fellow at the time of this study. |
 | Reprint requests: Henry W. Lim, MD, Department of Dermatology, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202-2689. |
Vol 47 - N° 2
P. 191-197 - août 2002 Retour au numéro
Article précédent
- Incontinentia pigmenti: A review and update on the molecular basis of pathophysiology
- Alexander L. Berlin, Amy S. Paller, Lawrence S. Chan
- Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity
- Sarah L. Chamlin, Jack Kao, Ilona J. Frieden, Mary Y. Sheu, Ashley J. Fowler, Joachim W. Fluhr, Mary L. Williams, Peter M. Elias
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?